Companies › Transcend Therapeutics
1 active drug program in 2 registered trials: 2 Phase 3; Psychiatry; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TSND-201 MDMA-like empathogen (methylone analog) | – | Phase 3 | Post Traumatic Stress Disorder | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07456696 | TSND-201 | Phase 3 | Post Traumatic Stress Disorder | Psychiatry | Dec 2027 |
| NCT07836647 | TSND-201 | Phase 3 | Post Traumatic Stress Disorder | Psychiatry | Feb 2028 |
No annotated target.
–
Curemark Emalex Biosciences Boston Medical Group Gedeon Richter Cybin IRL
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.